Changes in dickkopf-1 (DKK1) and sclerostin following a loading dose of vitamin D2 (300,000 IU)

Journal of Osteoporosis

Volumn 2014, Issue , 2014, Pages

  Sankaralingam, A ^a   Roplekar, R ^a   Turner, C ^b   Dalton, R N ^b   Hampson, G ^a,c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; DICKKOPF 1 PROTEIN; ERGOCALCIFEROL; SCLEROSTIN;

AGE; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; LOADING DRUG DOSE; MALE; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WNT SIGNALING PATHWAY;

EID: 84919722841     PISSN: 20908059     EISSN: 20420064     Source Type: Journal    
DOI: 10.1155/2014/682763     Document Type: Article

References (32)

1. P. H. Anderson, B. K. May, and H. A. Morris, "Vitamin D metabolism: new concepts and clinical implications," The Clinical Biochemist Reviews, vol. 24, no. 1, pp. 13-26, 2003
2. T. Shimada, H. Hasegawa, Y. Yamazaki et al., "FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis," Journal of Bone and Mineral Research, vol. 19, no. 3, pp. 429-435, 2004
3. P. W. Jurutka, L. Bartik, G. K. Whitfield et al., "Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands," Journal of Bone and Mineral Research, vol. 22, no. 2, pp. V2-V10, 2007
4. S. Takeda, T. Yoshizawa, Y. Nagai et al., "Stimulation of osteoclast formation by 1,25-dihydroxyvitaminDrequires its binding to vitamin D receptor (VDR) in osteoblastic cells: Studies using VDR knockout mice," Endocrinology, vol. 140, no. 2, pp. 1005-1008, 1999
5. H. A. Bischoff-Ferrari, T. Dietrich, E. J. Orav, and B. Dawson-Hughes, "Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults," The American Journal of Medicine, vol. 116, no. 9, pp. 634-639, 2004
6. H. A. Bischoff-Ferrari, W. C. Willett, J. B. Wong et al., "Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials," Archives of Internal Medicine, vol. 169, no. 6, pp. 551-561, 2009
7. K. M. Sanders, A. L. Stuart,E. J. Williamsonet al., "Annual highdose oral vitamin D and falls and fractures in older women: a randomized controlled trial," Journal of the American Medical Association, vol. 303, no. 18, pp. 1815-1822, 2010
8. H. Smith, F. Anderson, H. Raphael, P. Maslin, S. Crozier, and C. Cooper, "Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial," Rheumatology, vol. 46, no. 12, pp. 1852-1857, 2007
9. M. Rossini, D. Gatti, O. Viapiana et al., "Short-term effects on bone turnover markers of a single high dose of oral vitaminD3," Journal of Clinical Endocrinology andMetabolism, vol. 97, no. 4, pp. E622-E626, 2012
10. M. Rossini, S. Adami, O. Viapiana et al., "Dose-dependent short-term effects of single high doses of oral vitamin D3 on bone turnover markers," Calcified Tissue International, vol. 91, no. 6, pp. 365-369, 2012
11. C. Turner, N. Dalton, R. Inaoui, I. Fogelman, W. D. Fraser, and G. Hampson, "Effect of a 300 000-IU loading dose of ergocalciferol (vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency," Journal ofClinical Endocrinology andMetabolism, vol. 98, no. 2, pp. 550-556, 2013
12. G. J. Atkins, P. S. Rowe, H. P. Lim et al., "Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through aMEPE-ASARMdependent mechanism," Journal of Bone and Mineral Research, vol. 26, no. 7, pp. 1425-1436, 2011
13. F. Morvan, K. Boulukos, P. Clément-Lacroix et al., "Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass," Journal of Bone and Mineral Research, vol. 21, no. 6, pp. 934-945, 2006
14. T. Bellido, A. A. Ali, I. Gubrij et al., "Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis," Endocrinology, vol. 146, no. 11, pp. 4577-4583, 2005
15. F. S. Mirza, I. D. Padhi, L. G. Raisz, and J. A. Lorenzo, "Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women," The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 4, pp. 1991-1997, 2010
16. O. Viapiana, E. Fracassi, S. Troplini et al., "Sclerostin and DKK1 in primary hyperparathyroidism,"Calcified Tissue International, vol. 92, no. 4, pp. 324-329, 2013
17. B. Dawson-Hughes, S. S. Harris, L. Ceglia, and N. J. Palermo, "Effect of supplemental vitamin D and calcium on serum sclerostin levels," European Journal of Endocrinology, vol. 170, no. 4, pp. 645-650, 2014
18. O. Aguilera, C. Peña, J. M. García et al., "The Wnt antagonist DICKKOPF-1 gene is induced by 1,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells," Carcinogenesis, vol. 28, no. 9, pp. 1877-1884, 2007
19. K. Ohnaka, M. Tanabe, H. Kawate, H. Nawata, and R. Takayanagi, "Glucocorticoid suppresses the canonicalWnt signal in cultured human osteoblasts," Biochemical and Biophysical Research Communications, vol. 329, no. 1, pp. 177-181, 2005
20. Y. Karim,C. Turner, N. Dalton et al., "The relationship between pro-resorptive inflammatory cytokines and the effect of high dose vitamin D supplementation on their circulating concentrations," International Immunopharmacology, vol. 17, no. 3, pp. 693-697, 2013
21. E. Romagnoli, M. L. Mascia, C. Cipriani et al., "Short and longterm variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly," Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3015-3020, 2008
22. J. Qian, J. Xie, S. Hong et al., "Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma," Blood, vol. 110, no. 5, pp. 1587-1594, 2007
23. E. Tian, F. Zhan, R. Walker et al., "The role of theWnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma," The New England Journal of Medicine, vol. 349, no. 26, pp. 2483-2494, 2003
24. F. D. S. Rabelo, L. M. H. daMota, R. A. C. Lima et al., "TheWnt signaling pathway and rheumatoid arthritis," Autoimmunity Reviews, vol. 9, no. 4, pp. 207-210, 2010
25. G. Hampson, S. Edwards, S. Conroy, G. M. Blake, I. Fogelman, andM. L. Frost, "Therelationship between inhibitors of theWnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women," Bone, vol. 56, no. 1, pp. 42-47, 2013
26. D. Gatti, O. Viapiana, L. Idolazzi, E. Fracassi, M. Rossini, and S. Adami, "The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serumlevels ofDKK1," Journal ofClinical Endocrinology and Metabolism, vol. 96, no. 5, pp. 1555-1559, 2011
27. D. Gatti, O. Viapiana, E. Fracassi et al., "Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab," Journal of Bone and Mineral Research, vol. 27, no. 11, pp. 2259-2263, 2012
28. D. Gatti, O. Viapiana, S. Adami, L. Idolazzi, E. Fracassi, and M. Rossini, "Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin," Bone, vol. 50, no. 3, pp. 739-742, 2012
29. L. Gifre, S. Ruiz-Gaspa, A. Monegal et al., "Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover," Bone, vol. 57, no. 1, pp. 272-276, 2013
30. A. Catalano, N. Morabito,G. Basile, S. Brancatelli, D. Cucinotta, and A. Lasco, "Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis," Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 5, pp. 1911-1915, 2013
31. U. I. Mödder, K. A. Hoey, S. Amin et al., "Relation of age, gender, and bone mass to circulating sclerostin levels in women and men," Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 373-379, 2011
32. Z. C. Ryan, H. Ketha, M. S. McNulty et al., "Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 15, pp. 6199-6204, 2013.